Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE: Adebrelimab + Capecitabine in Resected Cholangiocarcinoma
NCT06607276Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in cholangiocarcinoma (CCA), sponsored by Jiangsu Provincial People's Hospital. Started Sep 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06607276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607276.